Company: LDDD
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001213900-25-013782
Chunk: 50

Company: Longduoduo Co Ltd
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 2
Chunk 50
---
3  
    Change 

    (Unaudited)  
    (Unaudited)  
    $  
    % 
  
    Total revenue 
    $1,775,495  
    $2,340,543  
    $(565,048) 
     (24)%
  
    Cost of revenue 
     28,781  
     42,399  
     (13,618) 
     (32)%
  
    Gross Profit 
     1,746,714  
     2,298,144  
     (551,430) 
     (24)%
  
    Total operating expenses 
     1,144,140  
     1,902,659  
     (758,519) 
     (40)%
  
    Loss from operations 
     602,574  
     395,485  
     207,089  
     52%
  
    Other income (expense), net 
     5,421  
     (136,584) 
     142,005  
     (104)%
  
    Loss before income taxes 
     607,995  
     258,901  
     349,094  
     135%
  
    Income tax 
     106,396  
     76,073  
     30,323  
     40%
  
    Net Loss 
    $501,599  
    $182,828  
    $318,771  
     174%

2

During the three months ended December 31, 2024, our total revenue
was $1,775,495, of which $28,781 was attributable to the sale of healthcare services, primarily derived from sales of “Immunological
Ozonated Autohemotherapy”, “Meridian-regulating and Consciousness-restoring Iatrotechnics”, “Assay”, “PRP”
and other healthcare services. The remaining $1,775,495 of revenue was attributable to commissions earned by the Company from its service
as sales agent for Honghai. In June of 2023, the Company began to engage in the sales agent business and focused on the sales of preventive
healthcare solutions administered by Honghai, with whom we have a Sales Agency Agreement. As of December 31, 2024, we operate through
five entities